Deferasirox Tablet, For Suspension
NDC Package 72205-391-05

11-digit billing NDC: 72205039105

Package Information

Deferasirox tablets is deferasirox is contraindicated in patients with:Estimated GFR less than 40 mL/min/1.73 m2[see Dosage and Administration (2.5), Warnings and Precautions (5.1)];Poor performance status; [see Warnings and Precautions (5.1, 5.3)]High-risk myelodysplastic syndromes; (this patient population was not studied and is not expected to benefit from chelation therapy)Advanced malignancies. This formulation utilizes a tablet, for suspension delivery system. Marketed by Novadoz Pharmaceuticals Llc, this product is identified by NDC 72205-391 and is authorized under FDA application ANDA209878.

Identification & Billing

NDC Package Code
72205-391-05
Package Description
10 BLISTER PACK in 1 CARTON / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACK
Product Code
11-Digit Billing Format
72205039105
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Deferasirox
Non-Proprietary Name
Deferasirox
Substance Name
Deferasirox
Dosage Form
Tablet, For Suspension - A tablet that forms a suspension when placed in a liquid (formerly referred to as a ‘dispersible tablet’).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Deferasirox is contraindicated in patients with:Estimated GFR less than 40 mL/min/1.73 m2[see Dosage and Administration (2.5), Warnings and Precautions (5.1)];Poor performance status; [see Warnings and Precautions (5.1, 5.3)]High-risk myelodysplastic syndromes; (this patient population was not studied and is not expected to benefit from chelation therapy)Advanced malignancies. [ see Warnings and Precautions (5.1 , 5.3)]Platelet counts less than 50 x 109/L [ see Warnings and Precautions (5.3, 5.4)]Known hypersensitivity to deferasirox or any component of deferasirox [see Warnings and Precautions (5.7), Adverse Reactions (6.2)].

Regulatory & Marketing

Labeler Name
Novadoz Pharmaceuticals Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA209878
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-20-2019
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72205-391). Click a package code to view its specific billing and regulatory data.

30 TABLET, FOR SUSPENSION in 1 BOTTLE
90 TABLET, FOR SUSPENSION in 1 BOTTLE
500 TABLET, FOR SUSPENSION in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72205-391-05 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet, for suspension in 1 blister pack of Deferasirox, a human prescription drug labeled by Novadoz Pharmaceuticals Llc. This tablet, for suspension is formulated for oral use and contains deferasirox as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novadoz Pharmaceuticals Llc on November 20, 2019. The current certification is valid through December 31, 2027.

How is this Novadoz Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72205039105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72205-391-05
11-Digit CMS (5-4-2)
72205-0391-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.